Cargando…
CRISPR/Cas13a-assisted rapid and portable HBV DNA detection for low-level viremia patients
BACKGROUND & AIMS: The WHO declared to eliminate hepatitis B virus (HBV) by 2030. However, an increasing number of patients are presenting with low-level viremia (LLV) with the widespread use of antiviral medications. The diagnostic efficiency and coverage area of HBV infection are low. Hence, t...
Autores principales: | Tian, Yuan, Fan, Zihao, Xu, Ling, Cao, Yaling, Chen, Sisi, Pan, Zhenzhen, Gao, Yao, Li, Hao, Zheng, Sujun, Ma, Yingmin, Duan, Zhongping, Zhang, Xiangying, Ren, Feng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9946317/ https://www.ncbi.nlm.nih.gov/pubmed/36735916 http://dx.doi.org/10.1080/22221751.2023.2177088 |
Ejemplares similares
-
A standardized assay for the quantitative detection of serum HBV RNA in chronic hepatitis B patients
por: Yu, Guangxin, et al.
Publicado: (2022) -
CRISPR/Cas13-assisted hepatitis B virus covalently closed circular DNA detection
por: Zhang, Xiangying, et al.
Publicado: (2022) -
Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies
por: Piermatteo, Lorenzo, et al.
Publicado: (2023) -
The potential effect of HBV vaccination on off-treatment HBsAg reversion after interferon-induced HBsAg clearance
por: Jiang, Shaowen, et al.
Publicado: (2023) -
Compartmentalisation of Hepatitis B virus X gene evolution in hepatocellular carcinoma microenvironment and the genotype-phenotype correlation of tumorigenicity in HBV-related patients with hepatocellular carcinoma
por: Fu, Ya, et al.
Publicado: (2022)